Scl 70 antibody--a specific marker of systemic sclerosis. 1986

M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner

Scl 70 antibodies were tested for in 107 patients with systemic sclerosis: 68 with acrosclerosis and 39 with diffuse scleroderma. Anticentromere antibodies (ACA) and other antinuclear antibodies (ANA) were tested for by indirect immunofluorescence on HEp-2 cells. Positive results for Scl 70 antibodies were obtained in 77% of cases of diffuse scleroderma and 44% of acrosclerosis. ACA and Scl 70 antibodies were found to be mutually exclusive. If acrosclerosis cases positive for anticentromere antibodies are excluded, the percentage of acrosclerosis cases positive for Scl 70 was 63%. ACA were found to be a marker of a benign, abortive subset of acrosclerosis with almost no cutaneous involvement (CREST), whereas Scl 70 did not discriminate between acrosclerosis and diffuse scleroderma. On HEp-2 cells Scl 70 positive sera gave a characteristic, fine speckled, almost homogeneous nuclear staining pattern.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002503 Centromere The clear constricted portion of the chromosome at which the chromatids are joined and by which the chromosome is attached to the spindle during cell division. Centromeres
D005260 Female Females
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis

Related Publications

M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
July 1983, The British journal of dermatology,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
January 1986, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College = Chung-kuo i hsueh k'o hsueh yuan, Chung-kuo hsieh ho i k'o ta hsueh hsueh pao,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
June 1986, Zhonghua yi xue za zhi,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
September 1987, Chest,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
May 2025, Clinical laboratory,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
January 2012, Clinical and experimental rheumatology,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
September 2013, Indian journal of dermatology,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
June 2010, Nihon rinsho. Japanese journal of clinical medicine,
M Jarzabek-Chorzelska, and M Blaszczyk, and S Jablonska, and T Chorzelski, and V Kumar, and E H Beutner
September 1997, The American journal of medicine,
Copied contents to your clipboard!